Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Capital Leases (2020 - 2025)

SAB Biotherapeutics' Capital Leases history spans 6 years, with the latest figure at $3.1 million for Q4 2025.

  • For Q4 2025, Capital Leases fell 4.7% year-over-year to $3.1 million; the TTM value through Dec 2025 reached $3.1 million, down 4.7%, while the annual FY2025 figure was $3.1 million, 4.7% down from the prior year.
  • Capital Leases reached $3.1 million in Q4 2025 per SABSW's latest filing, down from $3.2 million in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $3.8 million in Q4 2021 to a low of $3.1 million in Q4 2025.
  • Average Capital Leases over 5 years is $3.4 million, with a median of $3.4 million recorded in 2023.
  • Peak YoY movement for Capital Leases: fell 3.53% in 2022, then decreased 5.9% in 2024.
  • A 5-year view of Capital Leases shows it stood at $3.8 million in 2021, then decreased by 3.53% to $3.6 million in 2022, then decreased by 5.82% to $3.4 million in 2023, then dropped by 4.17% to $3.3 million in 2024, then decreased by 4.7% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Capital Leases are $3.1 million (Q4 2025), $3.2 million (Q3 2025), and $3.2 million (Q2 2025).